Noocholine Rompharm (Choline alfoscerate) 250 mg ampoules
English product name
Noocholin Rompharm
Release Form
Solution for in/in and in/m introduction
Description Choline alfoscerate
The solution for in/in and in/m injection is transparent, colorless or light yellow.
1 ml 1 amp.
choline alfoscerate anhydride (in the form of choline alfoscerate polyhydrate) 250 mg 1g
Auxiliary substances: water d/i - up to 1 ml
4 ml - colorless glass ampoules with a capacity of 5 ml (3) - packages, cell contour (1) - cardboard packs.
ATC codes
N07AX02 Choline alfoscerate
Clinical-pharmacological groups / Group affiliation
Nootropic drug. Central Action Cholinomimetic
Active substance
choline alfoscerate
Pharmaco-therapeutic group Choline alfoscerate
Nootropic agent
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
The shelf life is four years.
Pharmacological effect Choline alfoscerate
Nootropic drug, central action cholinomimetic with predominant effect on the CNS. The preparation contains 40.5% metabolically protected choline. Choline alfoscerate in the body, under the influence of brain enzymes, is broken down into choline and glycerophosphate. Choline is involved in the synthesis of acetylcholine, transmitting nerve impulses and improving brain function, and glycerophosphate is a precursor to phosphatidylcholine membrane neurons.
Choline alfoscerate improves cerebral blood flow, enhances metabolic processes in the brain, activates structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.
Results of clinical studies have shown that choline alfoscerate stimulates dose-dependent release of acetylcholine under physiological conditions of neurotransmission.
Testimony Choline alfoscerate
- acute period of head trauma with predominantly stem level lesions;
- psychoorganic syndrome amid degenerative and involutive brain changes;
- consequences of cerebrovascular insufficiency (impairment of intellectual function);
- multiinfarction dementia.
Method of use, course and dosage
The preparation is administered in/m and in/v (slowly) to 1 gr per day for fifteen to twenty days. The oral administration of choline alfoscerate is then performed.
- Nosology (ICD codes)
- F01
- Vascular dementia
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- I69
- Effects of cerebrovascular disease
- S06
- Intracranial injury
